Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
about
Structural Basis of Targeting the Exportin CRM1 in CancerIdentifying candidate genes for 2p15p16.1 microdeletion syndrome using clinical, genomic, and functional analysis.Genomic and molecular characterization of esophageal squamous cell carcinomaAtomic basis of CRM1-cargo recognition, release and inhibitionKPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agentsSINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agentsNucleo-cytoplasmic transport as a therapeutic target of cancershRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.The Cellular Distribution of RanGAP1 Is Regulated by CRM1-Mediated Nuclear Export in Mammalian Cells.Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compoundsExpression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.The Nuclear Proteome of a Vertebrate.Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy.Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants.Chromosome region maintenance 1 expression and its association with clinical pathological features in primary carcinoma of the liver.Preclinical activity of selinexor, an inhibitor of XPO1, in sarcomaERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition?Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.A clinician's guide to double hit lymphomas.Selective inhibitors of nuclear export (SINE) in hematological malignancies.Natural course and biology of CML.Breakthrough therapies in B-cell non-Hodgkin lymphoma.A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis.Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia.A "RANning" leap with "XPOrt" into TKI resistanceExcess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
P2860
Q26781513-407DDA73-D16B-4984-A212-6B4BF81CF40CQ27334126-26D443C8-BBBD-414F-A3CE-58068953BCAFQ28657686-B2F9BF76-9DCB-4417-924F-2027D6C9240CQ33940712-99C0BE17-2544-4B65-B4EA-7C4445AE686EQ34098446-ADA13ADC-327D-4BEB-86C4-B752B48B16A4Q34410193-7EC93B8E-DDFB-481F-8348-D184C5B510B0Q34441666-3136DB25-4E8E-49C7-9294-39ED18AEBC9CQ34452108-D20A06C4-78F6-4277-8562-F6867BB580D8Q35171271-14862B9F-F9E5-43A6-A822-1E30C6805A55Q35602930-29C96C2A-7F7C-4A08-B517-C69E6EB1B8ABQ35823090-30B92534-2B53-47D6-9ACA-83A64A9EA59DQ35843010-39D781AB-2926-421F-BB3F-4EB893624E51Q35920569-21E45DAB-C0D9-4EC2-A0E2-26C50824570FQ36200347-1ABB48B0-C90E-4C40-84C9-869D1F28FAF6Q36269679-C02E5A8B-95D9-4959-ACCD-8D0AD4282AB0Q36298896-B8610F33-F6F4-4A24-A6CE-F3E6A24981E6Q37002035-B4FFC64B-CDEC-4A3E-85F6-8C1B0EDBBA59Q37086082-91A5C5C7-077B-4ACE-AD58-770640FF3279Q37302065-E31A05D3-8C34-4E3B-9C56-BFFF5BA09DACQ37684621-412784F7-6EB6-41C4-A502-FF97F4FF0BADQ38222341-4FE9E178-E7AB-4386-919C-999BC302BEE9Q38260357-4F5E2FE3-7C8A-4938-9F05-FAFD29ABF4A1Q38296091-16E02CBC-D306-4E64-A08F-B5B0F6BBBE1BQ38368605-70A7ED24-AE86-4BCC-BF11-1A6FCFF16CC0Q38392667-66519AF5-3030-4EC5-A689-9C8932AB915CQ38708600-E149CDB8-B8C0-4C52-8343-6D574CFB52AFQ38812797-19920E17-1402-4D0E-A6CC-53512E3EBE9BQ38866390-62E7D7AF-9380-4E5B-8054-13A3D37FC7F3Q38878268-F49440B5-16D1-40C7-BADE-39C022E2893FQ38881093-E44894E6-0B53-4DBB-BA9D-E75A9C1C9CC3Q38943147-CE1239D2-EF0F-41B5-8313-3B4A81BC5252Q39281253-38700976-B8DF-4AC7-BDBF-1FF9791A7B93Q39411920-8D931635-0B6A-40FB-80A1-E90A59DD7FD2Q40963604-56CC9BE0-1D4D-4A8F-BB00-BE9B1585B455Q41087485-C41CD30E-F32B-489C-9A91-6D51AD1B08EDQ41360967-0C4C535D-1B45-40C6-8A68-4A4FEFDA9174Q41412563-973EC5C6-6783-4D24-9DE0-5F09C8747C17Q41553595-35AA0427-3F2E-4AD6-9760-22852D6A5CFDQ42178391-A1DC9AA1-7F64-4B07-BDBE-187E9ABEE592Q42199612-1261DC5A-D113-4526-A7A0-2CEF7FC47BB1
P2860
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Preclinical and clinical effic ...... itor KPT-330 in Ph+ leukemias.
@en
Preclinical and clinical effic ...... itor KPT-330 in Ph+ leukemias.
@nl
type
label
Preclinical and clinical effic ...... itor KPT-330 in Ph+ leukemias.
@en
Preclinical and clinical effic ...... itor KPT-330 in Ph+ leukemias.
@nl
prefLabel
Preclinical and clinical effic ...... itor KPT-330 in Ph+ leukemias.
@en
Preclinical and clinical effic ...... itor KPT-330 in Ph+ leukemias.
@nl
P2093
P2860
P50
P1433
P1476
Preclinical and clinical effic ...... itor KPT-330 in Ph+ leukemias.
@en
P2093
Alistair Reid
Ann-Kathrin Eisfeld
Carrie L Smith
Christopher J Walker
Danilo Perrotti
Denis Claude Roy
Dragana Milojkovic
Gregory Ferenchak
Jane Apperley
Jason G Harb
P2860
P304
P356
10.1182/BLOOD-2013-04-495374
P407
P577
2013-08-22T00:00:00Z